What is Korio?
Korio operates as a specialized provider of clinical trial software, specifically targeting the inefficiencies inherent in Randomization and Trial Supply Management (RTSM). By integrating deep domain expertise directly into its platform architecture, the company replaces legacy, manual delivery models with streamlined, automated workflows. This approach not only reduces the time-to-market for critical pharmaceutical assets but also ensures higher data integrity throughout the trial lifecycle. Korio's platform is designed to challenge the status quo of the RTSM market, offering a sophisticated alternative to traditional providers that have struggled to adapt to the rapid digitization of life sciences research.
How much funding has Korio raised?
Korio has raised a total of $6.8M across 1 funding round:
Other Financing Round
$6.8M
Other Financing Round (2023): $6.8M with participation from Excelerate Health Ventures and Boston Millennia Partners
Key Investors in Korio
Excelerate Health Ventures
Excelerate Health Ventures is a venture capital firm focused on investing in digital healthcare, particularly in AI-powered pharmaceutical technology and services.
Boston Millennia Partners
Boston Millennia Partners provides private equity financing to high growth companies in the healthcare and life sciences industry, leveraging decades of operational and financial expertise.
What's next for Korio?
With the support of its latest investment, Korio is poised to deepen its penetration into the enterprise clinical trial market. The strategic roadmap likely involves scaling its engineering teams to enhance platform capabilities, particularly in predictive analytics and real-time supply chain monitoring. Furthermore, the company is expected to leverage its recent capital to forge deeper partnerships with global pharmaceutical entities, aiming to standardize its software as the primary operating system for complex clinical trials. As the industry continues to prioritize speed and regulatory compliance, Korio's focus on reducing trial timelines positions it as a critical infrastructure player in the future of drug development.
See full Korio company page
